Free Research Report on ABIOMED, Inc., Acco Brands Corp., Acorda Therapeutics, Inc., Addus HomeCare Corp and First Majestic Silver Corp.

News provided by

Jan 31, 2013, 08:00 ET

NEW YORK, January 31, 2013 /PRNewswire/ --

Today, Traders Insight announced new research reports highlighting ABIOMED, Inc. (Nasdaq: ABMD), Acco Brands Corp. (NYSE: ACCO), Acorda Therapeutics, Inc. (Nasdaq: ACOR), Addus HomeCare Corp (Nasdaq: ADUS) and First Majestic Silver Corp. (NYSE: AG). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

ABIOMED, Inc. Research Report
ABIOMED, Inc. develops temporary and permanent cardiac support systems. The Company develops, manufactures and markets medical technologies designed to assist or replace the pumping function of the failing heart. It focuses on the development of two temporary support systems, the bi-ventricular support system (BVS) and the intra-arterial cardiac support system (ICs). The Full Research Report on ABIOMED, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.TradersInsight.net/r/2013-01-30/2439_ABMD]

Acco Brands Corp. Research Report
ACCO Brands Corporation is a supplier of office products to the office products resale industry. The Company designs, develops, manufactures and markets a variety of traditional and computer-related office products, supplies, binding and laminating equipment and related consumable supplies, personal computer accessory products, paper-based time management products and presentation aids and products. The Full Research Report on Acco Brands Corp. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.TradersInsight.net/r/2013-01-30/ad82_ACCO]

Acorda Therapeutics, Inc. Research Report
Acorda Therapeutics, Inc. (Acorda) is a commercial-stage biopharmaceutical company. The Company is engaged in the identification, development and commercialization of novel therapies that improve neurological function in people with multiple sclerosis (MS), spinal cord injury (SCI), and other disorders of the nervous system. Ampyra (dalfampridine) is an extended release tablet formulation of dalfampridine (4-aminopyridine, 4-AP). The Full Research Report on Acorda Therapeutics, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.TradersInsight.net/r/2013-01-30/fe67_ACOR]

Addus HomeCare Corp Research Report
Addus HomeCare Corporation is a provider of a range of social and medical services in the home focused primarily on the dual eligible population. The Company operates in two segments: home & community services and home health services. The Company's services include personal care and assistance with activities of daily living, skilled nursing and rehabilitative therapies, and adult day care. The Full Research Report on Addus HomeCare Corp - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.TradersInsight.net/r/2013-01-30/9261_ADUS]

First Majestic Silver Corp. Research Report
First Majestic Silver Corp. (First Majestic), is engaged in the business of silver production, development, exploration, and acquisition of mineral properties with a focus on silver production in Mexico. The Company has three operating segments located in Mexico, two development projects in Mexico, one retail market segment in Canada and one silver trading segment in Europe. The Full Research Report on First Majestic Silver Corp. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.TradersInsight.net/r/2013-01-30/2ab7_AG]

About Traders Insight
Our model of enabling open collaboration between members is breaking new ground into the investment community. By tapping into the resources of the community, we are crowd-sourcing our reach. As a result -- we have been able to identify some of the greatest moving companies on the market today. The evidence is in the results, join today and experience what you've been missing.